324 related articles for article (PubMed ID: 28939378)
1. Polymorphic phase transitions: Macroscopic theory and molecular simulation.
Anwar J; Zahn D
Adv Drug Deliv Rev; 2017 Aug; 117():47-70. PubMed ID: 28939378
[TBL] [Abstract][Full Text] [Related]
2. [Polymorph transformation of solid drugs].
Zhang Q; Mei XF
Yao Xue Xue Bao; 2015 May; 50(5):521-7. PubMed ID: 26234130
[TBL] [Abstract][Full Text] [Related]
3. An approach to developing a force field for molecular simulation of martensitic phase transitions between phases with subtle differences in energy and structure.
Tuble SC; Anwar J; Gale JD
J Am Chem Soc; 2004 Jan; 126(1):396-405. PubMed ID: 14709107
[TBL] [Abstract][Full Text] [Related]
4. Effect of organic acids on the solid-state polymorphic phase transformation of piracetam.
Fan F; Xu S; Guo M; Cai T
Int J Pharm; 2023 Nov; 647():123532. PubMed ID: 37871868
[TBL] [Abstract][Full Text] [Related]
5. Modeling solid-state transformations occurring in dissolution testing.
Laaksonen T; Aaltonen J
Int J Pharm; 2013 Apr; 447(1-2):218-23. PubMed ID: 23506958
[TBL] [Abstract][Full Text] [Related]
6. Manipulation of Pharmaceutical Polymorphic Transformation Process Using Excipients.
Tian B; Ding Z; Zong S; Yang J; Wang N; Wang T; Huang X; Hao H
Curr Pharm Des; 2020; 26(21):2553-2563. PubMed ID: 32053064
[TBL] [Abstract][Full Text] [Related]
7. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
Baghel S; Cathcart H; O'Reilly NJ
J Pharm Sci; 2016 Sep; 105(9):2527-2544. PubMed ID: 26886314
[TBL] [Abstract][Full Text] [Related]
8. Solid-solid Phase Transitions between Crystalline Polymorphs of Organic Materials.
Rietveld IB
Curr Pharm Des; 2023; 29(6):445-461. PubMed ID: 36545715
[TBL] [Abstract][Full Text] [Related]
9. Role of water in the physical stability of solid dosage formulations.
Airaksinen S; Karjalainen M; Shevchenko A; Westermarck S; Leppänen E; Rantanen J; Yliruusi J
J Pharm Sci; 2005 Oct; 94(10):2147-65. PubMed ID: 16136577
[TBL] [Abstract][Full Text] [Related]
10. Size-dependent phase stability of a molecular nanocrystal: a proxy for investigating the early stages of crystallization.
Zahn D; Anwar J
Chemistry; 2011 Sep; 17(40):11186-92. PubMed ID: 21922553
[TBL] [Abstract][Full Text] [Related]
11. A New, More Stable Polymorphic Form of Otilonium Bromide: Solubility, Crystal Structure, and Phase Transformation.
Vega DR; Halac E; Segovia L; Baggio R
J Pharm Sci; 2016 Oct; 105(10):3013-3020. PubMed ID: 27444388
[TBL] [Abstract][Full Text] [Related]
12. Recent progress of structural study of polymorphic pharmaceutical drugs.
Higashi K; Ueda K; Moribe K
Adv Drug Deliv Rev; 2017 Aug; 117():71-85. PubMed ID: 27940141
[TBL] [Abstract][Full Text] [Related]
13. Solution-mediated phase transformation: significance during dissolution and implications for bioavailability.
Greco K; Bogner R
J Pharm Sci; 2012 Sep; 101(9):2996-3018. PubMed ID: 22213419
[TBL] [Abstract][Full Text] [Related]
14. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy.
Heinz A; Strachan CJ; Gordon KC; Rades T
J Pharm Pharmacol; 2009 Aug; 61(8):971-88. PubMed ID: 19703341
[TBL] [Abstract][Full Text] [Related]
15. Solid State Concerns During Drug Discovery and Development: Thermodynamic and Kinetic Aspects of Crystal Polymorphism and the Special Cases of Concomitant Polymorphs, Co-Crystals and Glasses.
Otto DP; De Villiers MM
Curr Drug Discov Technol; 2017; 14(2):72-105. PubMed ID: 27908255
[TBL] [Abstract][Full Text] [Related]
16. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the phase transitions occurring during and after the dehydration of xylazine hydrochloride monohydrate.
Krūkle-Bērziņa K; Actiņš A
Int J Pharm; 2014 Jul; 469(1):40-9. PubMed ID: 24732032
[TBL] [Abstract][Full Text] [Related]
18. Phase transformation considerations during process development and manufacture of solid oral dosage forms.
Zhang GG; Law D; Schmitt EA; Qiu Y
Adv Drug Deliv Rev; 2004 Feb; 56(3):371-90. PubMed ID: 14962587
[TBL] [Abstract][Full Text] [Related]
19. Molecular nucleation mechanisms and control strategies for crystal polymorph selection.
Van Driessche AES; Van Gerven N; Bomans PHH; Joosten RRM; Friedrich H; Gil-Carton D; Sommerdijk NAJM; Sleutel M
Nature; 2018 Apr; 556(7699):89-94. PubMed ID: 29620730
[TBL] [Abstract][Full Text] [Related]
20. Understanding pharmaceutical polymorphic transformations I: influence of process variables and storage conditions.
Sood J; Sapra B; Bhandari S; Jindal M; Tiwary AK
Ther Deliv; 2014 Oct; 5(10):1123-42. PubMed ID: 25418270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
